Venker Eric's Form 4 filing
Roivant Sciences Ltd. (ROIV) · filed Nov 7, 2025
- Accession no.
- 0001140361-25-041214
- Filed
- Nov 7, 2025
- Trade date
- Nov 7, 2025
- Filing delay
- Same day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $4.04M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Venker EricCIK 0001801917 | Officer (President & Immunovant CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 7, 2025 | Common Shares | MOption exerciseAcquired | +200,000 | $3.85 | +$770,000 | 1,704,959 | Direct | |
| Nov 7, 2025 | Common Shares | SSaleDisposed | −200,000 | $20.22F1 | −$4,044,000 | 1,504,959 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 7, 2025 | Common Stock | MOption exerciseDisposed | −200,000 | $20.22 | −$4,044,000 | 6,076,523 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.
Referenced by the price of 1 transaction in Table I.